Workflow
Lishengpharma(002393)
icon
Search documents
002393,午后逆势涨停!
新华网财经· 2025-06-13 08:51
今日,A股三大指数回调。 盘面上, 蚂蚁金服概念股活跃,正元智慧(300645)午后一分钟内直线拉升,实现"20CM"涨停;A股 油气开采及服务板块表现强势,科力股份"30CM"涨停,通源石油"20CM"涨停。 美容护理、互联网电商、影视院线板块回调明显;昨日大涨的创新药板块今日下跌, 力生制药 (002393)午后逆势涨停。 今日,数字货币概念股局部回暖,蚂蚁金服概念股活跃。 正元智慧(300645)午后在一分钟内直线拉 升,实现"20CM"涨停;吉大正元收获"2连板",协鑫能科一字涨停,金时科技尾盘涨停。 | 金时科技 | | 13.96 +10.01% +13.13% | | | --- | --- | --- | --- | | 002951 | | | | | 人气龙头1 领涨龙头1 | 首板 最终涨停14:56 | | | | 华信永道 | 68.95 | +6.00% +17.48% | | | 837592 | | | | | 朗新集团 | 17.06 | +4.66% +5.18% | | | 300682 | | | | | 恒生电子 | 27.75 | +3.85% | +3.24% | ...
002393,午后逆势涨停!
新华网财经· 2025-06-13 08:51
今日,A股三大指数回调。 盘面上, 蚂蚁金服概念股活跃,正元智慧(300645)午后一分钟内直线拉升,实现"20CM"涨停;A股 油气开采及服务板块表现强势,科力股份"30CM"涨停,通源石油"20CM"涨停。 力生制药日前在深交所互动易平台表示,公司近年来实施内生外引并举战略,通过自主研发、合作开 发、许可引进、CMO孵化等方式,推进高端仿制药、创新药、合成生物学、细胞与基因治疗等业务布 局,向更高价值链延伸。推进"原料药+制剂"一体化,向技术壁垒高、附加值高的特色品种延伸。公司 研发强度持续保持7%以上,研发成果加速涌现。2022年获得批件6个,2023年获得批件4个,2024年获 得批件16个,创历史新高。 力生制药2024年年报显示,公司作为化学制药领域少数中华老字号品牌之一,专注于医药产品研发、生 产和销售,主要产品包括寿比山吲达帕胺片、三鱼氨酚咖匹林片等。 蚂蚁金服概念股活跃 今日,数字货币概念股局部回暖,蚂蚁金服概念股活跃。 正元智慧(300645)午后在一分钟内直线拉 升,实现"20CM"涨停;吉大正元收获"2连板",协鑫能科一字涨停,金时科技尾盘涨停。 美容护理、互联网电商、影视院线板块回调 ...
天津发展附属力生制药认购兴业银行理财产品
Zhi Tong Cai Jing· 2025-06-11 11:05
Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), has entered into several wealth management agreements with Industrial Bank, totaling a principal amount of RMB 185 million (approximately HKD 201 million) for investment products [1] Group 1 - On March 31, 2025, Lifescience Pharmaceutical entered into its first wealth management agreement with Industrial Bank, with a principal amount of RMB 20 million (approximately HKD 21.74 million) for structured deposits [2] - On May 7, 2025, Lifescience Pharmaceutical signed its second wealth management agreement with Industrial Bank and Xinyin Wealth Management, with a principal amount of RMB 10 million (approximately HKD 10.87 million) for fixed income investment products [2] - On May 7, 2025, Lifescience Pharmaceutical entered into its third wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 7, 2025, Lifescience Pharmaceutical signed its fourth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 29, 2025, Lifescience Pharmaceutical entered into its fifth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 35 million (approximately HKD 38.04 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its sixth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 50 million (approximately HKD 54.35 million) [2] - On June 11, 2025, Lifescience Pharmaceutical entered into its seventh wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its eighth wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 40 million (approximately HKD 43.48 million) [2]
力生制药: 关于使用闲置募集资金进行现金管理的进展公告
Zheng Quan Zhi Xing· 2025-06-11 08:23
Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing up to RMB 600 million for purchasing short-term financial products with high safety and liquidity, without affecting the implementation of investment projects [1] Group 1: Cash Management Details - The company has invested RMB 50 million in a structured deposit at Industrial Bank, with a term of approximately 186 days and an expected annual yield of 1.20%-1.80% [1] - The structured deposit is classified as a principal-protected floating income type with a low-risk rating (R1) [1] Group 2: Previous Cash Management Activities - As of the announcement date, the total amount of idle raised funds used for cash management that are not yet due is RMB 85 million, which is within the approved limits for cash management [3]
力生制药(002393) - 关于使用闲置募集资金进行现金管理的进展公告
2025-06-11 08:00
证券代码:002393 证券简称:力生制药 公告编号:2025-042 天津力生制药股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司(以下简称"公司")于2025年3月19日召开第七届董事 会第五十次会议、2025年4月11日召开2024年度股东大会,审议通过了《关于公司2025年 使用闲置募集资金进行现金管理额度的议案》,同意公司在不影响募集资金投资项目实施 的情况下,使用额度不超过人民币6亿元闲置募集资金购买安全性高、流动性好、由募集户 银行(招商银行、兴业银行或邮储银行)发行的短期理财产品,期限不超过股东大会批准 之日起12个月,在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月 21日在巨潮资讯网(www.cninfo.com.cn)披露的《关于公司2025年使用闲置募集资金进行 现金管理额度的公告》(公告编号:2025-025)。 一、本次进行现金管理购买理财产品情况 公司以募集资金共计5,000万元人民币在兴业银行股份有限公司天津分行(以下简称"兴 ...
力生制药(002393) - 关于使用闲置自有资金进行现金管理的进展公告
2025-06-11 08:00
证券代码:002393 证券简称:力生制药 公告编号:2025-043 天津力生制药股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司(以下简称"公司")于2025年3月19日召开第七届董事 会第五十次会议、2025年4月11日召开2024年度股东大会,审议通过了《关于公司2025年 使用闲置自有资金进行现金管理额度的议案》,同意公司使用额度不超过人民币10亿元闲 置自有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品, 包括但不限于通过银行、证券等专业理财机构购买的理财产品,期限不超过股东大会批准 之日起12个月,在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月 21日在巨潮资讯网(www.cninfo.com.cn)披露的《关于公司2025年使用闲置自有资金进行 现金管理额度的公告》(公告编号:2025-024)。 1.公司本次使用闲置自有资金进行现金管理所涉及的投资产品为金融机构发行的风险 可控的理财产品,收益情况由于受宏观经济的影 ...
自选股财报季|力生制药业绩会实录:公司将持续完善原料药-制剂一体化布局
Quan Jing Wang· 2025-06-09 04:25
Core Viewpoint - The company is actively enhancing its market value through various strategies, including mergers and acquisitions, value management tools, and consistent cash dividends to shareholders, resulting in a significant increase in market capitalization and stock price [2][4]. Group 1: Value Management and Market Performance - The company has focused on value creation, operational management, communication, and realization to enhance its market value [2]. - The company has acquired Jiangxi Qingshunkangyuan Pharmaceutical and established an industrial fund, which has contributed to revitalizing underperforming assets [2]. - From early April to the end of May, the company's market value increased by over 13%, and as of June 4, the stock price reached a six-year high [2]. Group 2: Strategic Focus and Industry Positioning - The company is concentrating on its core business and optimizing its industrial layout, with a dual-driven development model of "industry + capital" [3]. - The company is committed to enhancing its core competitiveness and has developed a systematic plan to improve the quality of the listed company [3]. Group 3: Innovation and R&D Investments - The company is actively engaged in innovative drug research and development, employing a strategy of "internal growth and external introduction" [4][9]. - In 2024, the company's R&D investment reached 127 million yuan, a year-on-year increase of 21.56%, with the number of R&D personnel rising to 354 [4]. - The company has achieved drug registration certificates for high-end generic drugs and is collaborating with the Chinese Academy of Sciences on projects in synthetic biology [4][9]. Group 4: Financial Management and Shareholder Returns - The company distributed 89.69 million yuan in dividends for the 2024 fiscal year and is open to mid-year dividend announcements based on performance [6][11]. - The company has a cash reserve of 1.9 billion yuan and is utilizing idle funds for stable financial investments while planning for strategic investments and new product development [7][10]. - The company completed a stock buyback from December 25, 2024, to January 9, 2025, repurchasing 7,209,980 shares, which is 2.80% of the total share capital [12][20].
力生制药首个分散片剂型新产品获批
Core Viewpoint - The approval of Ticagrelor dispersible tablets by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio and business expansion opportunities [1][2]. Group 1: Product Approval and Significance - The company has received approval for Ticagrelor dispersible tablets, becoming the third domestic company to obtain such approval under the new chemical drug registration classification, which is equivalent to passing the consistency evaluation [1]. - This approval is the company's first for a dispersible tablet formulation, indicating a strategic move to diversify its product offerings [1]. Group 2: Research and Development Achievements - The company has established a key laboratory platform in Tianjin for the research of high-end formulations, leading to the successful development of a rapid disintegration formulation of Ticagrelor [2]. - The bioequivalence tests demonstrated that the product is equivalent to the original formulation in both fasting and postprandial states, ensuring safety and efficacy [2]. Group 3: Strategic Initiatives and Market Potential - Since 2020, the company has aggressively pursued new product development and has achieved breakthroughs in drug procurement, with multiple products receiving new registration certificates [2]. - The approval of Ticagrelor dispersible tablets is a critical step in the company's "raw material + formulation" strategy, aiming for a comprehensive breakthrough in the cardiovascular treatment sector, which is expected to open new market opportunities and profit growth [2].
力生制药替格瑞洛分散片获批上市 心脑血管治疗领域实现“原料自主化+剂型差异化+生产规模化”全链条突破
Quan Jing Wang· 2025-06-06 08:18
Core Viewpoint - The approval of the Ticagrelor dispersible tablets by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio and expanding its business scope in the cardiovascular field [1][3]. Group 1: Product Approval and Market Impact - The company received the drug registration certificate for Ticagrelor dispersible tablets (90mg), making it the third domestic generic drug approved under the new chemical drug registration classification [1]. - The market for oral anticoagulants in core hospitals in China exceeded RMB 10 billion in 2023, indicating a substantial market opportunity for Ticagrelor dispersible tablets, which are classified as a Category B product under national medical insurance [3]. - The sales figures for Ticagrelor in China are projected to be RMB 1.151 billion in 2022, RMB 1.050 billion in 2023, and RMB 1.174 billion in 2024, reflecting a stable market demand [3]. Group 2: Research and Development - The company has invested significantly in R&D, with a budget of RMB 127 million for 2024, representing a 20% increase from the previous year, and maintaining a research intensity of over 7% in recent years [3]. - The successful development of the Ticagrelor dispersible tablet involved rigorous testing and the establishment of strict quality standards, achieving bioequivalence with the original formulation [2]. - The company has been proactive in its R&D efforts since 2020, with multiple products, including Ticagrelor, receiving drug registration certificates and passing consistency evaluations [4]. Group 3: Strategic Positioning - The approval of Ticagrelor dispersible tablets is a key step in the company's "raw material + formulation" strategy, indicating a comprehensive breakthrough in the cardiovascular treatment sector [4]. - The company aims to enhance its core competitiveness through continuous innovation and strategic positioning, focusing on both industrial and capital-driven development [3][4]. - Future plans include deepening the synergy between R&D and industrialization to provide accessible quality medications for patients while creating long-term value for investors [4].
力生制药:替格瑞洛分散片通过上市许可申请
news flash· 2025-06-06 07:48
Core Viewpoint - The announcement indicates that the company has received a drug registration certificate from the National Medical Products Administration for Ticagrelor dispersible tablets (90mg), which has been approved for market licensing. This drug is intended for use in patients with acute coronary syndrome or a history of myocardial infarction, along with at least one high-risk factor for atherosclerotic thrombotic events, to reduce the incidence of cardiovascular death, myocardial infarction, and stroke [1] Company Impact - The launch of Ticagrelor dispersible tablets will enhance the company's product line for treating circulatory system diseases, thereby increasing its market competitiveness [1] - The introduction of this drug is expected to have a positive impact on the company's future operating performance [1]